CagriSema vs Orforglipron
A side-by-side research comparison of CagriSema and Orforglipron across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CagriSema | Orforglipron |
|---|---|---|
| Full name | CagriSema (Cagrilintide + Semaglutide) | Orforglipron (Oral Non-Peptide GLP-1 Agonist) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Phase 3 Clinical Trial |
| Mechanism | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. | Small molecule agonist of GLP-1 receptors that mimics native GLP-1 binding without requiring peptide structure. Achieves full receptor activation with standard oral bioavailability. |
| Molecular weight | Combination product | ~550 Da |
| Half-life | 7 days (both components) | 25-60 hours |
| Bioavailability | High (SubQ) | Moderate-High (oral) |
| Typical dose | Cagrilintide 2.4mg + Semaglutide 2.4mg | 12-45 mg |
| Frequency | Once weekly | Once daily |
| Route | Subcutaneous | Oral |
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Orforglipron reported benefits
- Oral administration (no injection)
- No fasting requirement
- Significant weight loss (8-14%)
- Small molecule stability
- Lower manufacturing cost potential
Related comparisons
Research and educational reference only. Not medical advice.